Wearable cardioverter-defibrillator reduced total mortality in post-MI patients with low LVEF
Efficacy of a Wearable Cardioverter-Defibrillator after Myocardial Infarction: Results of the Vest Prevention of Early Sudden Death Trial (VEST)
Presented at ACC.18 by Jeffrey Olgin (San Francisco, CA, USA)News - Mar. 11, 2018
- After a mean follow-up of 84.3 ±15.6 days, no difference was seen for SCD between the WCD group (n=1524) and the control group (n=778) (1.6% vs. 2.4%, P=0.18)
- No significant differences were found cause-specific death (except for stroke) and non-fatal outcomes between the 2 groups.
- Total mortality was significantly reduced in the WCD group (3.1%) compared to the control group (4.9%) (P=0.04).
- Adverse events that were observed in the WCD group were: rash in any location, rash on torso, itch in any location, itch on torso.
In post-MI patients with a LVEF≤35%, a WCD did not significantly reduced SCD, but was associated with a lower total mortality after 3 months. These findings indicate that WCD in high-risk patients with a low LVEF post-MI could give protection until evaluation for ICD at 40-90 days.
In a press release dr. Olgin said: ““It is possible that sudden deaths were misclassified as it’s difficult to define sudden death with accuracy when a death is unwitnessed and there is little documentation. But the cause of death is irrelevant if we can prevent it. This study found that the device was associated with fewer deaths among people recovering from a heart attack with low ejection fraction. It’s also the first therapy associated with a mortality benefit above and beyond standard medical therapy immediately after heart attack.”
Our coverage of ACC.18 is based on the information provided during the congress.